Drug Discovery World

OCTOBER 30, 2023

Kura Oncology’s FIT-001 Phase I dose-escalation trial of KO-2806, a farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumours, has commenced with the dosing of the first patient. The post Farnesyl transferase inhibitor for solid tumours enters trials appeared first on Drug Discovery World (DDW).

Trials 130

Trials Pharmacokinetics Therapies Treatment 130

Drug Discovery World

JUNE 26, 2024

Spinogenix has initiated a Phase II trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD), following approval for the trail in Australia. The study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of SPG302 in adult AD participants.

Small Molecule 189

Small Molecule Pharmacokinetics Drugs Clinical Trials 189

Drug Discovery World

FEBRUARY 27, 2024

Arvinas has commenced dosing in the Phase I clinical trial of ARV-102, its first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. The post First PROTAC degrader for neurodegenerative disease enters trials appeared first on Drug Discovery World (DDW).

Trials 130

Trials Disease Clinical Trials Pharmacokinetics 130

Drug Discovery World

MARCH 8, 2024

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP).

Trials 130

Trials Pharmacokinetics Clinical Trials Clinical Development 130

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Chief Investigator Dr Bristi Basu, University of Cambridge, and Co-Chief Investigator Dr Debashis Sarker, King’s College London, are leading the trial.

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

SCIENMAG: Medicine & Health

NOVEMBER 1, 2023

A small clinical trial with a pharmacokinetic sub-study, led by a world-renowned pharmacologist at the University of Houston, has demonstrated the promising effectiveness of the drug Riluzole for improving functionality in people with acute spinal cord injuries (SCI) if the drug is taken within 12 hours post-injury.

Clinical Trials 86

Clinical Trials Trials Pharmacokinetics Drugs 86

Drug Discovery World

MARCH 8, 2023

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Regulations 130

Drug Discovery World

APRIL 12, 2023

Evecxia Therapeutics has reported favourable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a Phase I trial of EVX-101 in healthy volunteers treated with escitalopram. Details of the trial In EVX-101, the 5-HTP dose is fixed at 250mg, while variable levels of carbidopa control 5-HTP plasma exposure levels.

Trials 130

Trials Clinical Pharmacology Medical Schools Pharmacokinetics 130

Drug Discovery World

JULY 25, 2023

The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics, and psychedelic effect of ascending oral doses of CYB003.

Trials 130

Trials Clinical Trials Pharmacokinetics FDA 130

Drug Discovery World

AUGUST 20, 2024

Early drug discovery takes an average of three-to-six years and accounts for 42% of total costs 1 in the development of a new drug. Research shows that companies could shorten this cycle by up to 30 months 2 over the course of the small molecule drug discovery process by applying AI.

Small Molecule 275

Small Molecule Pharmaceutical Companies Drugs Pharmaceuticals 275

Drug Discovery World

OCTOBER 25, 2023

Iksuda Therapeutics has dosed the first patient in a Phase I trial of antibody drug conjugate (ADC) IKS014 in patients with advanced solid tumours that express HER2. This follows positive data from Phase I clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through Phase II and Phase III trials in China.

Pharmacokinetics 130

Pharmacokinetics Trials Drugs Clinical Trials 130

Drug Discovery World

AUGUST 8, 2024

The first cohort of participants has been dosed in a Phase I trial MTX-474, a human IgG1 antibody designed to neutralise EphrinB2 signalling to treat fibrosis. The study, taking place in Australia, is designed to assess the safety, tolerability, pharmacokinetics, and target engagement of MTX-474 in healthy participants.

Treatment 147

Treatment Pharmacokinetics Trials Disease 147

Drug Discovery World

APRIL 8, 2024

It is progressing to Phase I clinical trials with JD Bioscience. Beyond its therapeutic potential and pharmacokinetic attributes, including over 60% oral bioavailability, compound 11c exhibits hepatocyte and plasma stability, minimal cytotoxicity, and low cytochrome P450 inhibition.

Disease 130

Disease Treatment Pharmacokinetics Clinical Trials 130

Drug Discovery World

AUGUST 13, 2024

Animal models (AMs) have generally been seen as useful for drug development and biomedical research for many years. They are assumed to closely mimic human disease progression and act as a good testing ground for toxicology studies and pharmacokinetics 1. Drugs developed in animals often fail in human studies. Possibly not.

Drug Development 162

Drug Development Animal Testing Regulations Drugs 162

Drug Discovery World

FEBRUARY 2, 2024

Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of a rare blood cancer drug and a novel production process for CAR-T therapies.

Pharmacokinetics 130

Pharmacokinetics Drugs International Clinical Trials 130

Drug Discovery World

JULY 25, 2023

Justin Hay , Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs Director, at Certara, examine recent changes in paediatric guidelines and how they affect drug development projects. In addition to describing the ethical framework (eg.

Drug Development 130

Drug Development Clinical Pharmacology Pharmacokinetics Drugs 130

Drug Discovery World

DECEMBER 22, 2023

Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex.

Pharmacokinetics 130

Pharmacokinetics Clinical Development FDA Trials 130

Broad Institute

JULY 17, 2024

Still, more than 90 percent of drug candidates fail in clinical trials, with even more that never make it to the clinical stage. Many drugs fail because they simply aren’t safe. Seal began this work after wondering if more toxicology insights could be gleaned from a drug candidate’s chemical structure.

Pharmacokinetics 84

Pharmacokinetics Molecular Biology Drugs FDA 84

Conversations in Drug Development Trends

AUGUST 9, 2024

Authors: Matt Cooper, PhD, Executive Director, Therapeutic Strategy Lead, Oncology; Megan Morrison, Vice President, Asia Pacific Strategy Lead Adaptive trial designs have become essential in oncology, offering a flexible and efficient approach for conducting clinical trials.

Trials 80

Trials Clinical Trials Regulations FDA 80

Drug Discovery World

SEPTEMBER 6, 2022

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avacta Group’s chemotherapy drug, AVA6000, for the treatment of soft tissue sarcoma. . This designation qualifies the developer of the drug for certain incentives, like seven years of market exclusivity upon drug approval from the FDA.

FDA 130

FDA Pharmacokinetics Drugs Clinical Trials 130

Drug Discovery World

JANUARY 9, 2023

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for iOnctura’s IOA-244, which is in development for solid and hematologic malignancies including uveal melanoma. . A PI3Kδ inhibitor, IOA-244 ( roginolisib) is being investigated in the DIONE-01 trial, a two-part, first-in-human Phase I study.

FDA 130

FDA Drugs Pharmacokinetics Trials 130

Drug Discovery World

FEBRUARY 14, 2024

The post Data shows restored motor function in mouse models of Parkinson’s disease appeared first on Drug Discovery World (DDW). The post Data shows restored motor function in mouse models of Parkinson’s disease appeared first on Drug Discovery World (DDW).

Disease 147

Disease Clinical Trials Pharmacokinetics Trials 147

Drug Discovery World

JUNE 29, 2023

DDW’s Diana Spencer provides an overview of the latest innovations in drug discovery for mental health. To mark the occasion, this article summarises the most recent news about the ways drug discovery is improving wellbeing and mental health through innovative new treatments and therapies.

Drugs 130

Drugs Pharmacokinetics Trials FDA 130

Drug Discovery World

OCTOBER 2, 2023

The EC decision is based on the results from the Phase III ASCERTAIN clinical trial investigating the pharmacokinetic exposure equivalence of the novel oral fixed-dose combination versus intravenous (IV) decitabine in AML patients.

Treatment 130

Treatment Pharmacokinetics Clinical Trials Licensing 130

Drug Discovery World

NOVEMBER 3, 2023

We’re pleased to share these first clinical data from our clinical trial of NDI-101150. The post HPK1 inhibitor demonstrates clinical benefit in solid tumours appeared first on Drug Discovery World (DDW). The data were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.

Pharmacokinetics 130

Pharmacokinetics Clinical Trials Trials Disease 130

Drug Discovery World

APRIL 5, 2023

A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. It also supports the drug’s potential to treat other cancers. We hope that our drug goes on to show effectiveness in clinical trials.”

Clinical Trials 130

Clinical Trials Pharmacokinetics Drugs DNA 130

Drug Discovery World

JANUARY 31, 2024

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO).

Treatment 130

Treatment Clinical Trials Pharmacokinetics Trials 130

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. In addition, they discovered that cladribine, a clinical drug, activates DGKB and inhibits DGAT1. GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 130

FDA Approval FDA Drugs Pharmacokinetics 130

Drug Discovery World

AUGUST 23, 2022

The MAA is supported by results from a Phase III clinical trial investigating the pharmacokinetic (PK) exposure equivalence of the novel oral fixed-dose combination versus IV decitabine. The post Combination treatment for AML closer to approval following EMA nod appeared first on Drug Discovery World (DDW). References . ?

Treatment 130

Treatment Pharmacokinetics Clinical Trials DNA 130

Drug Discovery World

SEPTEMBER 26, 2022

DDW Editor Reece Armstrong explores the rise of drug repurposing and the benefits and disadvantages it brings to drug discovery and development. . Drug repurposing, the act of finding new clinical targets for both approved and unapproved drugs, has emerged as a viable alternative to traditional drug discovery approaches. .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Discovery World

DECEMBER 14, 2023

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. The results from this trial evaluating vepdegestrant in combination with palbociclib help advance our goals of benefitting patients with ER+/HER2- breast cancer. The results show a 25.1%

Therapies 130

Therapies Trials Pharmacokinetics Treatment 130

Drug Discovery World

NOVEMBER 10, 2023

CAN-2409 in non-metastatic pancreatic cancer Candel Therapeutics reported on initial positive interim data from its Phase II clinical trial of CAN-2409 that showed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC). The estimated overall survival rate was 71.4%

Pharmacokinetics 130

Pharmacokinetics Clinical Trials Immune Response Treatment 130

Drug Discovery World

JULY 20, 2023

What are benefits of drug repurposing and why do clinical drug trials so often fail? Diana Spencer summarises the key messages from the ‘Drug Repurposing: Challenges and Opportunities’ Symposium held at the 19th World Congress of Basic & Clinical Pharmacology (WCP) 2023.

Clinical Pharmacology 100

Clinical Pharmacology Clinical Trials Drugs Trials 100

Drug Discovery World

MAY 24, 2023

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The Phase I/II clinical trial The trial utilised a dose-escalation approach to evaluate the intravenous administration of mRNA-3927.

Therapies 130

Therapies Clinical Trials Pharmacokinetics Trials 130

Drug Discovery World

MAY 31, 2023

Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The Phase I/II trial AU-007 is the first computationally designed human monoclonal antibody in a human clinical trial.

Pharmacokinetics 130

Pharmacokinetics Trials Clinical Trials Treatment 130

Drug Discovery World

MARCH 10, 2023

Efficacy and pharmacokinetic data from the study are in line with global data, and EV-203 is a bridging study to EV-301, a Phase III randomised study that has supported global registrations of enfortumab vedotin, and EV-201 Cohort 1. The post Astellas’ urothelial cancer drug approved in China appeared first on Drug Discovery World (DDW).

Pharmacokinetics 130

Pharmacokinetics Drugs Licensing Licensing 130